complete systemic imaging (including brain MRI) before third-generation EGFR-TKI treatment;
received standard third-generation EGFR-TKI therapy (monotherapy or combined with brain radiotherapy);
willing to cooperate with the follow-up after third-generation EGFR-TKI treatment;
informed consent of the patient.
You may not be if
Multiple primary or metastatic tumors (except early skin cancer, cervical carcinoma in situ that has been treated radically, with no recurrence or progression for more than 5 years);
Pregnant or lactating women who, as judged by the investigator, were not candidates for brain MRI;
Uncontrolled epilepsy, central nervous system disease, or history of mental disorders, judged by the researcher to potentially interfere with the signing of the informed consent form or affect patient compliance.;
patients without EGFR sensitive mutations or with unknown EGFR mutation status.
Withdrawal criteria
The investigators considered that the patients had poor adherence to the study protocol.
The patient withdrew informed consent and asked to withdraw.
There was any safety reason (adverse event) considered by the investigator;
Due to other underlying diseases, side effects, economic factors, and other reasons, patients did not receive regular doses of third-generation EGFR-TKI (continuous withdrawal time more than 1 week, cumulative withdrawal time more than 2 weeks, etc.).
The patient was not followed up according to the protocol.
Other circumstances in which withdrawal from the study was deemed necessary by the investigator.
